

## PRESS RELEASE

innate pharma

---

### **INNATE PHARMA ANNOUNCES APPOINTMENT OF LAURE-HÉLÈNE MERCIER TO THE EXECUTIVE BOARD**


- ***Appointments of Dr. Mondher Mahjoubi, Chief Executive Officer, and Dr. Yannis Morel, EVP Business Development and Portfolio Strategy, renewed to the Executive Board for three years***

**Marseille, France, February 12, 2019, 7:00 AM CET**

---

Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announces that the Supervisory Board of Innate Pharma has strengthened the Company's leadership and corporate governance with the appointment of Laure-Hélène Mercier, Chief Financial Officer, as a member of the Executive Board for a period of three years.

Laure-Hélène Mercier, MSc, M. M.ère



# PRESS RELEASE

innate pharma

---

## Information about Innate Pharma shares:

<b>ISIN code</b>	FR0010331421
<b>Ticker code</b>	IPH
<b>LEI</b>	9695002Y8420ZB8HJE29

## Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the *Document de Reference* prospectus filed with the AMF, which is available on the AMF website [www.amf-france.org](http://www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

## For additional information, please contact:

### Investors

#### **Innate Pharma**

Dr. Markus Metzger / Danielle Spangler / Jérôme Marino

Tel.: +33 (0)4 30 30 30 30

[investors@innate-pharma.com](mailto:investors@innate-pharma.com)

### International Media

#### **Consilium Strategic Communications**

Mary-Jane Elliott / Jessica Hodgson

Tel.: +44 (0)20 3709 5700

[InnatePharma@consilium-comms.com](mailto:InnatePharma@consilium-comms.com)

### French Media

#### **ATCG Press**

Solène Moulin

Tel.: +33 (0)9 81 87 46 72

[presse@atcg-partners.com](mailto:presse@atcg-partners.com)